Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10754809 | Biochemical and Biophysical Research Communications | 2014 | 7 Pages |
Abstract
We show here that the ARF promoter has lower activity in normal growing fibroblasts and shows higher cancer cell-specificity compared to the E2F1 promoter. We also demonstrate that adenovirus expressing HSV-TK under the control of the ARF promoter shows lower cytotoxicity than that of the E2F1 promoter, in normal growing fibroblasts but has equivalent cytotoxicity in cancer cell lines. These results suggest that the ARF promoter, which is specifically activated by deregulated E2F activity, is an excellent candidate to drive therapeutic cytotoxic gene expression, specifically in cancer cells.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Kenta Kurayoshi, Eiko Ozono, Ritsuko Iwanaga, Andrew P. Bradford, Hideyuki Komori, Kiyoshi Ohtani,